Results 131 to 140 of about 1,007 (149)

Understanding and addressing social determinants to advance cancer health equity in the United States: A blueprint for practice, research, and policy

Ca-A Cancer Journal for Clinicians, 2020
Kassandra I Alcaraz, K Robin Yabroff, Carmen E Guerra   +2 more
exaly  

Management of common clinical problems experienced by survivors of cancer

Lancet, The, 2022
Jon D Emery, Phyllis Butow, Larissa Nekhlyudov   +2 more
exaly  

Cancer Statistics for African Americans

Ca-A Cancer Journal for Clinicians, 2002
Ahmedin Jemal Dvm
exaly  

HPV Communication: Review of Existing Research and Recommendations for Patient Education

Ca-A Cancer Journal for Clinicians, 2004
Annekathryn Goodman
exaly  

Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study

Lancet, The, 2020
Ronghui Du, , Jiuyang Xu
exaly  

Dolutegravir versus raltegravir in antiretroviral-experienced, integrase-inhibitor-naive adults with HIV: week 48 results from the randomised, double-blind, non-inferiority SAILING study

Lancet, The, 2013
Andrey Shuldyakov, Carlos Brites, Jaime F Andrade-Villanueva   +2 more
exaly  

Global pattern of experienced and anticipated discrimination reported by people with major depressive disorder: a cross-sectional survey

Lancet, The, 2013
Antonio Lasalvia, Tine Van Bortel, Kristian Wahlbeck   +2 more
exaly  

Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-1: 24-week results from a randomised, double-blind, placebo-controlled trial

Lancet, The, 2007
Anthony M Mills
exaly  

Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-2: 24-week results from a randomised, double-blind, placebo-controlled trial

Lancet, The, 2007
Adriano Lazzarin, Bonaventura Clotet
exaly  

Efficacy and safety of darunavir-ritonavir compared with that of lopinavir-ritonavir at 48 weeks in treatment-experienced, HIV-infected patients in TITAN: a randomised controlled phase III trial

Lancet, The, 2007
Kiat Ruxrungtham
exaly